此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions

2026年9月3日 更新者:Mintech Bio Ltd

A Pilot Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions

Mintech-Bio Ltd is a UK-based start-up company which was created to turn 14 years of research from our co-founder Dr Alvaro Mata at Queen Mary University into a real-world product.

Loss of tooth enamel from issues such as decay or erosion is a great cause of dental problems, affecting over half of people around the world. There is also evidence to suggest that having poor oral health may be connected to other health issues such as diabetes, heart problems, and lung infections like pneumonia.

While treatments like fluoride varnishes and remineralization solutions can help with the effects of enamel loss, there's currently no easy-to-use option that actually regrows enamel in a way that closely matches the natural look and strength of real enamel.

Mintech-Bio has created a special gel that helps rebuild tooth enamel back to its natural strength and structure. This new invention could take the place of fluoride treatments and make a big difference in preventing tooth problems around the world. The purpose of this research study is to demonstrate the efficacy of the Epinamel device in the treatment of dental white-spot lesions.

If you meet all the screening criteria you will be entered into the study and shall have the device applied after the removal of dental braces. Each trial participant will have the treatment product applied to a tooth on one side of the mouth, and a comparative 'control' product named Curodont Repair (vVardis Professional, Switzerland will be applied on the opposite side of the mouth.

研究概览

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • London、英国、SE1 9RT
        • 招聘中
        • Guys and St Thomas NHS Foundation Trust Faculty of Dentistry, Oral & Craniofacial Sciences, Kings College London
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • • Will have dental braces or brackets removed immediately prior to or up to 48 hours prior to potential study participation

    • Have at least one active non-cavitated carious lesions around the bracket area with a rough, chalky and matte surface (white spot lesions - WSLs) at each side of the mouth;
    • Have carious lesion which are fully visible, assessable and accessible;
    • Are able and willing to observe good oral hygiene throughout the study;
    • Have ≥20 teeth and a BPE score of <3;
    • Have completed fixed orthodontic treatment within the past 24-120 hours.
    • Are aged 12-60 years
    • Are willing and able to attend the on-study visits;
    • Are willing and able to understand all study-related procedures;
    • Provide written informed consent (by parent/guardian if minor) before participation in the study.
    • No systemic diseases or concomitant medication affects salivary flow in order not to negatively affect the remineralising process.

Exclusion Criteria:

  • • Patients with known hypersensitivity to glutaraldehyde or any of the product's ingredients.

    • Patients with severe pulpitis or oral infections
    • Patients who are still be undergoing treatment using dental braces or brackets at time of study initiation
    • Patients who are vulnerable
    • Patients who are participating in another trial
    • Patients with tetracycline pigmentation, dental fluorosis, or enamel hypoplasia
    • Participants who had evidence of reduced salivary flow, systemic, or medical complications
    • Participants with cavitated lesions

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment group
Epinamel one side of mouth Curadont opposite side of mouth

Epinamel is a professional dental product that is indicated for the treatment of white spot lesions. It utilizes a patented technology that promotes enamel repair by entrapping calcium and phosphate from the saliva to grow hydroxyapatite mineral within the white spot lesion and on the tooth surface.

Epinamel is a 2-part product. Applying and drying Part A on the surface of the tooth followed by Part B initiates the hardening and setting of the product.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Regression or progression of white spot lesions (WSLs), determined by changes in lesion size measured (micrometers) by morphometry.
大体时间:6 weeks

Classified as the proportion of lesions that:

Regress (decrease in size by >20% at 6 weeks with respect to baseline), Progress (increase in size by >20% at 6 weeks with respect to baseline), or Remain approximately stable in size (decrease or increase in size by ≤20% at 6 weeks with respect to baseline).

Assessment method: Morphometric measurement (micrometers) of standardized, calibrated clinical photographs.

6 weeks

次要结果测量

结果测量
措施说明
大体时间
Laser Fluorescence Readings (DIAGNOdent Pen, KaVo, Biberach, Germany) Objective fluorescence-based assessment of lesion status.
大体时间:6 weeks

Repeat measurements will be used to monitor lesion progression or regression over time.

Numerical values range from 0 to 99, with clinical interpretation as follows:

0-12: Healthy tooth structure / sound enamel 13-24: Initial enamel caries / demineralization 25-29: Deep enamel caries, possible dentin involvement

≥30: Likely dentin caries / advanced lesion

A two-sided paired samples t-test will be used to compare laser fluorescence measurements at baseline and 6 weeks following treatment. A p-value of <0.05 will be considered statistically significant

6 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月6日

初级完成 (估计的)

2027年1月31日

研究完成 (估计的)

2027年1月31日

研究注册日期

首次提交

2026年7月7日

首先提交符合 QC 标准的

2026年7月22日

首次发布 (实际的)

2026年7月28日

研究记录更新

最后更新发布 (实际的)

2026年9月4日

上次提交的符合 QC 标准的更新

2026年9月3日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CIP01_Rev01
  • 10072636 (其他赠款/资助编号:Innovate UK)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅